A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
Public ClinicalTrials.gov record NCT03803202. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Randomized, Single Ascending Dose Study in Adults (Stage 1) and Randomized, Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, a Pneumococcal Vaccine
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of 3 different dose levels of ASP3772 in comparison to the active comparator Prevnar 13® (PCV13) in adults 18 to 64 years of age in Stage 1. Stage 2 will evaluate the safety, tolerability, and immunogenicity of 3 different dose levels of ASP3772 in comparison to the active comparator PCV13 in elderly 65 to 85 years of age. In addition, Stage 2 will evaluate the immunogenicity of 3 different dose levels of ASP3772 relative to the response seen following administration of Pneumovax® 23 (PPSV23) for the serotypes not included in PCV13.
Study identification
- NCT ID
- NCT03803202
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 630 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 23, 2019
- Primary completion
- Sep 27, 2020
- Completion
- Sep 27, 2020
- Last update posted
- Dec 20, 2023
2019 – 2020
United States locations
- U.S. sites
- 26
- U.S. states
- 11
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Advanced Clinical Research-Rancho Paseo | Banning | California | 92220 | — |
| Artemis Institute | San Diego | California | 92103 | — |
| Artemis Institute | San Marcos | California | 92078 | — |
| Research Centers of America | Hollywood | Florida | 33024 | — |
| Meridian Clinical Research | Savannah | Georgia | 31406 | — |
| Sundance Clinical Research | St Louis | Missouri | 63141 | — |
| Meridian Clinical Research | Norfolk | Nebraska | 68701 | — |
| United Medical Associates | Binghamton | New York | 13901 | — |
| PMG Research of Raleigh | Raleigh | North Carolina | 27604 | — |
| PMG Research of Hickory, LLC | Rocky Mount | North Carolina | 27804 | — |
| Piedmont HealthCare, PA | Statesville | North Carolina | 28625 | — |
| Wilmington Health | Wilmington | North Carolina | 28401 | — |
| PMG Research of Winston-Salem, LLC | Winston-Salem | North Carolina | 27103 | — |
| Tekton Research - George Town | Yukon | Oklahoma | 73099 | — |
| PMG Research | Knoxville | Tennessee | 37912 | — |
| PMG Research | Knoxville | Tennessee | 37938 | — |
| Advanced Clinical Research Institute | Cedar Park | Texas | 78613 | — |
| Texas Healthcare, PLLC | Fort Worth | Texas | 76104 | — |
| Benchmark Research | Fort Worth | Texas | 76135 | — |
| Texas Center for Drug Development | Houston | Texas | 77081 | — |
| Healthcare Associatiates of Texas | McKinney | Texas | 75070 | — |
| DM Clinical Research | Pearland | Texas | 77584 | — |
| Benchmark Research | San Angelo | Texas | 76904 | — |
| Clinical Trials of Texas | San Antonio | Texas | 78229 | — |
| Martin Diagnostic Clinic | Tomball | Texas | 77375 | — |
| CRA of Tidewater Inc | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03803202, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 20, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03803202 live on ClinicalTrials.gov.